Last edition
News about "Houman Ashrafian"
Sanofi's Lunsekimig Shows Promising Phase II Results in Asthma and Nasal Polyps Studies
The novel dual-targeting Nanobody met primary and key secondary endpoints in asthma and chronic rhinosinusitis trials, demonstrating improved outcomes and a favourable safety profile.
Houman Ashrafian | 08/04/2026 | By News Bureau
Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study
Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.
Houman Ashrafian | 18/02/2026 | By News Bureau | 143
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi has agreed to acquire Dynavax, strengthening its adult immunisation portfolio with an approved hepatitis B vaccine and a shingles vaccine candidate in phase I/II development. The deal combines Dynavax’s vaccine assets with Sanofi’s global development and commercial capabilities.
Houman Ashrafian | 24/12/2025 | By News Bureau
Sanofi Names Montpellier Global Hub for Autoimmune Disease Research
Sanofi, in partnership with the Immun4Cure University Hospital Institute in Montpellier, has launched a Translational Centre of Excellence focused on developing treatments for autoimmune and inflammatory diseases. The centre aims to place patients at the core of R&D, spanning early research through advanced clinical trials.
Houman Ashrafian | 16/10/2025 | By Dineshwori | 304
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy